Heart Transplantation Therapeutic Pipeline Review for H1 2013

2013-05-29
Published : May-2013

This report provides information on the therapeutic development for Heart Transplantation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Heart Transplantation. Heart Transplantation – Pipeline Review, Half Year is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

 

 

Scope of the report “Heart Transplantation – Pipeline Review, H1 2013” (http://www.reportsnreports.com/reports/249492-heart-transplantation-pipeline-review-h1-2013.html) covers:

– A snapshot of the global therapeutic scenario for Heart Transplantation.
– A review of the Heart Transplantation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
– Coverage of products based on various stages of development ranging from discovery till registration stages.
– A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
– Coverage of the Heart Transplantation pipeline on the basis of route of administration and molecule type.
– Key discontinued pipeline projects.
– Latest news and deals relating to the products.

Companies Involved in Heart Transplantation Therapeutics Development Covered in this report include: Novartis AG, Astellas Pharma Inc., Alexion Pharmaceuticals, Inc., Portola Pharmaceuticals, Inc., NasVax Ltd. and ToleroTech Inc.

Drug Profiles covered in this report: TT-32, Zortress, Anti-aCD3 Mab, JAK3 Specific Inhibitors, AS-2521780 and siRejection.

List of Tables in the report:
Number of Products Under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Novartis AG, H1 2013 13
Astellas Pharma Inc., H1 2013 14
Alexion Pharmaceuticals, Inc., H1 2013 15
Portola Pharmaceuticals, Inc., H1 2013 16
NasVax Ltd., H1 2013 17
ToleroTech Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Heart Transplantation Therapeutics – Drug Profile Updates 31
Heart Transplantation Therapeutics – Dormant Products 33

List of Figures in the report:
Number of Products under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Pre-Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

Contact [email protected] for further information.

List of Tables
Number of Products Under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Late Stage Development, H1 2013 10
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 11
Products under Development by Companies, H1 2013 12
Novartis AG, H1 2013 13
Astellas Pharma Inc., H1 2013 14
Alexion Pharmaceuticals, Inc., H1 2013 15
Portola Pharmaceuticals, Inc., H1 2013 16
NasVax Ltd., H1 2013 17
ToleroTech Inc., H1 2013 18
Assessment by Monotherapy Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Heart Transplantation Therapeutics – Drug Profile Updates 31
Heart Transplantation Therapeutics – Dormant Products 33

List of Figures
Number of Products under Development for Heart Transplantation, H1 2013 7
Products under Development for Heart Transplantation – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Late Stage Products, H1 2013 10
Pre-Clinical Stage Products, H1 2013 11
Assessment by Monotherapy Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

Filed in: Pharmaceuticals and Healthcare, Therapeutics
Tags: 
More Reports
Title Price Buy Now

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

“The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......
 $4950

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases,  growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders,  rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on  product in 2021.” Based on products, the topical drug delivery the market is segmented into ......
 $4950

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

“Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......
 $4950

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027

The global Healthcare cloud computing market is projected to reach USD 89.4  billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......
 $4950

Digital Pathology Market by Product (ArtificiaI Intelligence, Scanner, Software, Storage), Type (Human, Veterinary), Application (Teleconsultation, Training, Disease Diagnosis, Drug Discovery), End User (Pharma, Academia, Hospitals) – Global Forecast to 2026

“The Digital Pathology market is projected to grow at a CAGR of 13.2% during the forecast period (2021–2026).” The global digital pathology market is projected to reach USD 1,371 million by 2026 from USD 736 million in 2021, at a CAGR of 13.2% during the forecast period. The growth in the digital pathology market is mainly driven by factors such as the increasing adoption of digital pathology to enhance lab efficiency, rising incidence of cancer, and growing applications of digital pathology in drug development and companion diagnostics. On the other hand, the high costs of digital pathology systems are expected to restrain market growth to a certain extent. “The scanners segment accounted for the largest share of the Digital Pathology market in 2020.” Based on products,......
 $4950

Telehealth & Telemedicine Market by Component (Software & Services (RPM, Real-Time), Hardware (Monitors)), Delivery (On-Premise, Cloud-Based), Application (Teleradiology, Telestroke, TeleICU), End User (Provider, Payer) & Region – Global Forecasts to 2027

“The telehealth & telemedicine market is projected to grow at a CAGR of 26.6% during the forecast period (2022–2027).” The global telehealth & telemedicine market is expected to grow at a CAGR of 26.6% during the forecast period, to reach USD 285.7 billion by 2027 from an estimated USD 87.8 billion in 2022.The key factors driving the growth of this market include the need to expand healthcare access, the growing prevalence of chronic diseases and conditions, a shortage of physicians, advancements in telecommunications, government support and raising awareness, and rising technology adoption in the wake of COVID-19. However, regional variations in regulations, fraud, and the use of social media for care providers will restrict the market growth during the forecast period. ......
 $4950

Teleradiology Market by Product & Service (Services, Hardware, Software (PACS, RIS)), Imaging Technique (MRI, CT, X-ray, Ultrasound, Mammography, Nuclear Imaging), End User (Hospitals, Diagnostic Centers& Laboratories), COVID-19 Impact – Forecast to 2026

“A shortage of skilled radiologists & need for faster and improved diagnosis are driving market growth” The teleradiology market is expected to reach USD 14.8billion by 2026 from USD 7.3 billion in 2021, at a CAGR of 15.3% during the forecast period of 2021 to 2026. Due to the outbreak of coronavirus globally, there is a sudden rise in the demand for teleradiology services. The growth of this market is mainly attributed to the growth of the teleradiology market is driven by the rising geriatric population and the subsequent increase in the prevalence of associated diseases; the increasing number of advanced imaging procedures and a shortage of skilled radiologists; advancements in teleradiology the increasing adoption of cloud-based solutions. However, declining reimbursements a......
 $4950

Healthcare Consulting Services Market by Type of Service (Digital Health, IT, Operations, Strategy, Financial, HR & Talent), End User (Government Bodies, Healthcare Providers, Pharmaceutical & Biotechnology Companies), and Region – Global Forecasts to 2026

Global healthcare consulting services market is projected to grow at CAGR of 11.5%” The global healthcare consulting services market is projected to reach USD 41.2 billion by 2026 from USD 23.9 billion in 2021, at a CAGR of 11.5% during the forecast period. Healthcare consulting firms specialize in providing business consulting services to the healthcare industry in areas such as finance, accounting, marketing, insurance, healthcare management, billing, coding, regulations & compliance, healthcare standards, and many other similar areas. Growth in the healthcare consulting services market can be primarily attributed to the growing budget cuts, increasing pricing pressure, changing healthcare policies/regulations, and rising technological disruption across the healthcare industry t......
 $4950

Animal Growth Promoters and Performance Enhancers Market by Type (Antibiotic and Non-antibiotic (Hormones, Acidifiers, Feed Enzymes, Probiotics & Prebiotics, Phytogenic)), Animal Type (Poultry, Porcine, Livestock, Aquaculture) – Global Forecast to 2026

“The global animal growth promoters and performance enhancers market is projected to grow at a CAGR of 5.7%” The global animal growth promoters and performance enhancers market is projected to reach USD 21.4 billion by 2026 from USD 16.2 billion in 2021, at a CAGR of 5.7%. Animal health products, including growth promoters and performance enhancers, are types of drugs and chemicals used for animal growth. These enhancers help to digest food more effectively and enable animals to grow faster, which, in turn, help to improve productivity. Growth in the animal growth promoters and performance enhancers market is majorly driven by the rising demand for animal consumption and consumption of livestock-based products, rising global demand for naturally produced growth promoters, and rising......
 $4950

Hemophilia A and B – Epidemiology Forecast to 2030

Hemophilia A and B - Epidemiology Forecast to 2030 Summary Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation because of deficiencies in the production or function of coagulation factor VIII in hemophilia A or factor IX in hemophilia B (Bolton-Maggs and Pasi, 2003). Because of the deficiency of coagulation factor, hemophilia patients have a tendency to bleed in joints, muscles, soft tissues, and within mucous membranes, which can be either spontaneous or due to internal or external trauma, depending on the severity of the disease (CDC, 2021; Mayo Clinic, 2021). According to the World Federation of Hemophilia (WFH), hemophilia is rare. About 1 in 10,000 people are born with hemophilia A and about 1 in 50,000 people are born with hemophilia B......
 $3995
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy